About Forward Therapeutics
Forward Therapeutics is a company based in Palm Beach Gardens (United States) founded in 2022 by Toufike Kanouni and Ewan Taylor. Forward Therapeutics has raised $50 million across 1 funding round from investors including Orbimed, RA Capital and BVF Partners. Forward Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Palm Beach Gardens, United States
- Founders Toufike Kanouni, Ewan Taylor
- SectorsHealthcare
- Website forward-tx.com
- Social LinkedIn
- Total Equity Funding$50M (USD)
in 1 rounds
- Latest Funding Round$50M (USD), Series A
Nov 2023
- InvestorsOrbimed
& 2 more
Funding Insights of Forward Therapeutics
Forward Therapeutics has successfully raised a total of $50M through 1 strategic funding round. The most recent funding activity was a Series A round of $50 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50M
- Total Rounds 1
- Last Round Series A — $50M
- First Round $50M
(Nov 2023)
- Investors Count 3
All 1 funding rounds of Forward Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $50M | Series A | – | BVF Partners |
3 investors in total: 3 institutional.
Investors in Forward Therapeutics
Forward Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, RA Capital and BVF Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | – | bvflp.com | San Francisco, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for Forward Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Forward Therapeutics
2 people are tracked at Forward Therapeutics (2 in leadership).
| Name | Role | Group |
|---|---|---|
Toufike Kanouni | Co-Founder & CEO | Leadership |
Ewan Taylor | Co-Founder | Leadership |
Complete people profiles for Forward Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Forward Therapeutics
2 dated milestones of Forward Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Forward Therapeutics is founded.
- Funding First funding round of $50.0M.
Competitors of Forward Therapeutics
Forward Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| septerna.com | 2020 | San Bruno, United States | $250M | – | GPCR drug discovery platform is developed for multiple diseases. | |
| upstreambio.com | 2021 | Waltham, United States | $400M | – | Therapeutics for allergic and inflammatory diseases are developed. | |
| acelyrin.com | 2020 | Los Angeles, United States | $550M | – | Immunological drug candidates are developed for severe diseases. | |
| gossamerbio.com | 2017 | San Diego, United States | $330M | 102 | Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer | |
| calcimedica.com | 2006 | San Diego, United States | $76.66M | 11 | CRAC channel inhibitors are developed for inflammatory diseases. |
Detailed competitors of Forward Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Forward Therapeutics
Websites that share an audience with Forward Therapeutics (forward-tx.com).
Websites whose visitors overlap most with Forward Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| kaleidoscope.bio | 100% | 4.2K | #4,477,112 | View details |
Latest news on Forward Therapeutics
Complete news archive for Forward Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Forward Therapeutics
10 companies that operate in the same segment as Forward Therapeutics (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Forward Therapeutics
Forward Therapeutics was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Forward Therapeutics is headquartered in Palm Beach Gardens, United States. It is registered at Palm Beach Gardens, Florida, United States.
Toufike Kanouni is the current CEO of Forward Therapeutics. They have also founded this company.
Forward Therapeutics is a funded company, having raised a total of $50M across 1 funding round to date. The company's 1st funding round was a Series A of $50M, raised on Nov 2023.
Developer of therapeutics for chronic inflammatory disorders. It offers small molecule immune therapies as oral agents for immunological disorders.
Forward Therapeutics's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Forward Therapeutics has 3 investors. Key investors include Orbimed, RA Capital, and BVF Partners.